Lunit, a company specializing in medical artificial intelligence (AI) solutions, said on Thursday that the number of domestic and foreign medical institutions using its AI imaging solutions for mammography and chest X-ray has surpassed 1,000.

Lunit Insight CXR diagnoses 10 chest diseases such as lung nodules, menopause, and pneumothorax with 97-99 percent accuracy with the help of AI, according to the company.

Lunit Insight MMG detects the presence of breast cancer in mammography images with 96 percent accuracy to assist  doctors, the company said.

The company released the chest X-ray imaging solution, Lunit Insight CXR, and mammography imaging analysis solution, Lunit Insight MMG, in 2019.

Now, the company  is now supplying the two products to more than 1,000 medical institutions worldwide.

Of the total institutions, 80 percent are overseas customers in the order of Asia, Europe, the Middle East, and Latin America.

Overall, Japan showed the highest demand for Lunit’s AI-imaging solutions.

Lunit's two products won approval from the U.S. FDA in November 2021, from Health Canada, June,  and the Taiwan Food and Drug Administration (TFDA),  August.

Additionally, Lunit has signed key partnerships with GE Healthcare, Philips, and Fujifilm, large multinational companies which cumulatively account for about 50 percent of the global chest X-ray and mammography devices market share, which is rapidly expanding.